|
|
|
 |
Search published articles |
 |
|
Showing 2 results for SHIRVANI ARANI
Fatemeh Soltani, Kamal Yavari, Mahdi Sadeghi, Ali Bahrami Samani, Simindokht Shirvani Arani ,
Volume 16, Issue 1 (6-2018)
Abstract
In recent years, nanotechnology has gained serious attention for diagnosis, prevention and treatment roles. In this study we synthesized nanoceria or CeO2NPs (cerium oxide nanoparticles) and compared toxicity of cerium oxide powder in nano and bulk forms in two cancerous and one normal cell lines. The cell lines were cultured in a standard humidified incubator, at 37 °C in a 5% CO2 atmosphere, in RPMI 1640 medium. The cells were incubated with different concentrations of cerium oxide (from 2 μg/mL to 64 μg/mL) in bulk and nano forms. To determine the effect of cerium oxide on cell viability after 24 h, 48 h, and 72 h incubation, a MTT assay was performed using SKBR3 (human breast cancer cell line), A431 (Human epidermoid carcinoma cell line) and C2Cl2 (ATCC mouse skeletal muscle cell line) cells. Analysis of variance followed by Sidak post-hoc test, shows the toxicity of nanoceria is significantly deferent from bulk form on three cell lines in this study and is more on cancerous cells in compared to normal cells especially in higher level of concentrations after 24, 48 and 72 hours (All P<0.05). Additionally, the effect of cell lines, cerium oxide forms and concentrations cerium oxide leads in significantly the lowest amount of viability after 72 hours compared with 24 hours and 48 hours.
Fatemeh Soltani, Simindokht Shirvani Arani, Mahdi Sadeghi, Samira Heidari, Ali Bahrami Samani, Kamal Yavari,
Volume 16, Issue 1 (6-2018)
Abstract
The purpose of the present work was to introduce 141Ce-EDTMP as a novel potential future pain palliative agent to patients suffering from disseminated skeletal metastases and diagnostic imaging radioisotope as well. Cerium-141 [T1/2 = 32.501 days, Eβ (max) = 0.580 (29.8%) and 0.435(70.2%) MeV, Eγ = 145.44 (48.2%) keV] possesses radionuclidic properties suitable for use in palliative therapy of bone metastases. 141Ce also has gamma energy of 145.44 keV, which resembles that of 99mTc. Therefore, the energy window is adjustable on the Tc-99m energy because of imaging studies. 141Ce can be produced through a relatively easy route that involves thermal neutron bombardment on natural CeO2 in medium flux research reactors (4–5×1013 neutrons/cm2·s). The requirement for an enriched target does not arise. Ethylenediamine (tetramethylene phosphonic acid) (EDTMP) was synthesized and radiolabeled with 141Ce. The experimental parameters were optimized to achieve maximum yields (>99%). The radiochemical purity of 141Ce-EDTMP was evaluated by radio-thin layer chromatography. The stability of the prepared formulation was monitored for one week at room temperature, and results showed that the preparation was stable during this period (>99%). Biodistribution studies of the complexes carried out in wild-type rats exhibited significant bone uptake with rapid clearance from blood. The images showed high uptake of complex in bone after 72h and 2 weeks clearly. The percentage injected dose per gram of tissue (%ID/g) for each organ or tissue was calculated. The results show significant bone uptake with rapid clearance from blood. The properties of produced 141Ce-EDTMP suggest applying a new efficient bone pain palliative therapeutic agent to overcome metastatic bone pains.
|
|
